Executives
-
Altshuler DavidEVP, Chief Scientific Officer -
Kewalramani ReshmaCEO & President
-
Biller JonathanEVP and Chief Legal Officer
-
Leiden Jeffrey MExecutive Chairman
-
Bozic CarmenEVP and CMO
-
Atkinson Edward Morrow IiiEVP, Chief Technical Ops. Off.
-
Sachdev AmitEVP Chief Patient & Ext Af Off
-
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
-
Ambrose KristenSVP & Chief Accounting Officer
?
Mckenzie Diana
Director
Vertex Pharmaceuticals Incorporated
US, Boston [HQ]
CIK
1754648
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
3,604
Price per Share :
$418.27
Equivalence :
$1,507,445.08
Transaction History
-
A3,604 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/01/24
-
Footnotes
-
-
Footnotes:#1 Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.#2 Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2023, Ms. McKenzie deferred the receipt of 1,168 shares of common stock and received instead 1,168 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,168 shares of common stock in exchange for an equal number of deferred stock units.
-
D2,436 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/01/24
-
Footnotes
-
-
Footnotes:#1 Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.#2 Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2023, Ms. McKenzie deferred the receipt of 1,168 shares of common stock and received instead 1,168 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,168 shares of common stock in exchange for an equal number of deferred stock units.